8-K: Metagenomi Regains Full Rights to Gene Editing Tech After Moderna Collaboration Ends, Reports Strong Cash Position

Metagenomi has terminated its collaboration with Moderna, regaining full rights to its gene editing technologies, and reports a strong cash position of $327.4 million as of March 31, 2024.

Summary

• Metagenomi and Moderna mutually terminated their Strategic Collaboration and License Agreement on April 26, 2024.
• As a result, Metagenomi has regained full development and commercialization rights to its base editing and RNA-mediated integration systems (RIGS).
• The company will not receive any further payments from Moderna following the termination.
• Metagenomi expects to report approximately $327.4 million in cash and cash equivalents as of March 31, 2024.
• The company is on track to nominate a development candidate for Hemophilia A by mid-2024.
• They anticipate presenting 12-month non-human primate (NHP) durability data for Hemophilia A in the second half of 2024.
• Metagenomi plans to nominate an additional development candidate in late 2024.
• The company is focused on advancing its core technologies, including RIGS and CRISPR-Associated Transposases (CAST).
• Metagenomi has a strong cash position and expects its cash runway to extend into 2027.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with the regaining of full rights to their technology and a strong cash position. However, the termination of the Moderna collaboration and the preliminary nature of the financial results introduce some uncertainty.

Positives

• Metagenomi has regained full control over its core gene editing technologies, allowing for independent development and commercialization.
• The company has a strong cash position of $327.4 million, providing financial stability and runway into 2027.
• The Hemophilia A program is progressing well, with a development candidate nomination expected soon and positive durability data anticipated.
• Metagenomi's technology advancements, including ultra-small base editors and RIGS, offer potential advantages in delivery, safety, and dosing.
• The company has a broad pipeline of therapeutic targets across various diseases, including liver, neuromuscular, and other organ targets.

Negatives

• The termination of the Moderna collaboration means Metagenomi will not receive any future payments from that partnership.
• The financial results for the quarter ended March 31, 2024, are preliminary and unaudited, and may be subject to change.
• The company operates in a competitive and rapidly changing environment, which presents risks and uncertainties.

Risks

• The company's ability to develop and advance its programs and product candidates is subject to risks and uncertainties.
• Maintaining and establishing collaborations or strategic partnerships is crucial for the company's success.
• Regulatory approvals and filings are subject to uncertainty and may impact the company's timelines.
• The company operates in a competitive and rapidly changing environment, which presents risks and uncertainties.
• The preliminary financial results are subject to change upon completion of the audit.

Future Outlook

Metagenomi anticipates several key milestones by 2026, including two IND filings, at least two additional development candidates, in vivo proof of concept for large gene integrations, and additional business development opportunities. The company's cash runway is expected to extend into 2027.

Management Comments

• Metagenomi is focused on advancing its core technologies that are central to its toolbox.
• The company is leveraging its Hemophilia A experience to deliver and integrate a variety of target genes.
• Metagenomi continues to execute on all fronts.

Industry Context

The termination of the collaboration with Moderna allows Metagenomi to pursue its own strategic direction in the competitive gene editing space. The company's focus on proprietary technologies like RIGS and CAST positions it to potentially address a wide range of genetic diseases. The company is presenting at ASGCT, a key industry conference, which highlights the importance of their technology in the field.

Comparison to Industry Standards

• Metagenomi's base editors demonstrate a 5x increase in genome targetability compared to Cas9 systems, which is a significant improvement over standard CRISPR technology.
• The company's ultra-small CRISPR nucleases and base editors offer potential advantages in delivery, safety, manufacturing, and dosing compared to larger systems like Cas9.
• Metagenomi's work on large, targeted genome integrations using CAST is at the forefront of the field, with the first-ever report of targeted integration of >900 bp with all-RNA delivery.
• The company's approach to gene editing, including both RNA-mediated and DNA-mediated integration systems, provides a versatile platform for addressing a wide range of genetic diseases, which is a key differentiator in the industry.
• The company's focus on safe harbor loci for gene integration is a common approach in the industry to minimize off-target effects.

Stakeholder Impact

• Shareholders may view the regaining of full rights to the gene editing technology as a positive development.
• Employees may be impacted by the strategic shift following the termination of the Moderna collaboration.
• Customers and partners may be interested in the company's independent development plans.
• The strong cash position provides financial stability for the company's operations.

Next Steps

• Metagenomi will nominate a development candidate for Hemophilia A by mid-2024.
• The company will present 12-month NHP durability data for Hemophilia A in the second half of 2024.
• Metagenomi plans to nominate an additional development candidate in late 2024.
• The company will continue to advance its core technologies, including RIGS and CAST.
• Metagenomi will pursue additional business development opportunities.
• The company will present additional base editing and RIGS data at ASGCT on May 8 and May 9, 2024.

Key Dates

Keywords

gene editing, Metagenomi, Moderna, RIGS, base editing, CRISPR, Hemophilia A, biotechnology, therapeutic, genome integration, CAST, RNA-mediated integration, cash position